174 related articles for article (PubMed ID: 26831249)
1. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
Tothfalusi L; Endrenyi L
AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
[TBL] [Abstract][Full Text] [Related]
2. Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer risk.
Tothfalusi L; Endrenyi L
Stat Med; 2017 Nov; 36(27):4378-4390. PubMed ID: 28850696
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
[TBL] [Abstract][Full Text] [Related]
4. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs.
Ocaña J; Muñoz J
Pharm Stat; 2019 Oct; 18(5):583-599. PubMed ID: 31190418
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.
Endrenyi L; Tothfalusi L
J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):117-126. PubMed ID: 30798390
[TBL] [Abstract][Full Text] [Related]
6. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
Li Z; Fang L; Jiang W; Kim MJ; Zhao L
Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
[TBL] [Abstract][Full Text] [Related]
7. Likelihood approach for evaluating bioequivalence of highly variable drugs.
Du L; Choi L
Pharm Stat; 2015; 14(2):82-94. PubMed ID: 25408492
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax
Zhang Y; Chen X; Tang Y; Lu Y; Guo L; Zhong D
Drug Des Devel Ther; 2017; 11():2109-2119. PubMed ID: 28744102
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
10. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
Lechat P
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
[TBL] [Abstract][Full Text] [Related]
11. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
Molins E; Cobo E; Ocaña J
Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4-Way Replicate Crossover Investigation by a Reference-Scaled Average Bioequivalence Approach.
Ding YH; Liu B; Lou JF; Sun JX; Wu M; Zhu XX; Chen GL; Zhang H; Li XJ; Chen H; Liu CJ; Shen ZW; Li CY
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):713-720. PubMed ID: 30325583
[TBL] [Abstract][Full Text] [Related]
13. The bioequivalence of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
[TBL] [Abstract][Full Text] [Related]
14. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
Muñoz J; Alcaide D; Ocaña J
Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study.
Wang L; Di Y; Guo T; Ming JE; Kong F; Yin H; Zhang L; Xie F; Yang N; Ping C; Li Y; Hou J
Adv Ther; 2020 Jun; 37(6):2696-2709. PubMed ID: 32418143
[TBL] [Abstract][Full Text] [Related]
16. Approximate confidence limit for the reference scaled bioequivalence with a parallel design.
Liao JJZ; Li Y
J Biopharm Stat; 2020 Mar; 30(2):231-243. PubMed ID: 31455199
[TBL] [Abstract][Full Text] [Related]
17. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects.
Tang F; Zhou R; Cheng Z; Yang G; Chen A; Liu Z; Tan H; Yang S; Li S; Mu L; Yu P
Acta Pharm Sin B; 2016 Jan; 6(1):71-8. PubMed ID: 26904401
[TBL] [Abstract][Full Text] [Related]
18. Some thoughts on drug interchangeability.
Chow SC; Song F; Chen M
J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
[TBL] [Abstract][Full Text] [Related]
19. Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
Jones B; Li B; Bagger M; Goodyear A; Ludwig I
Pharm Stat; 2022 Nov; 21(6):1357-1365. PubMed ID: 35604539
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan 80 mg Capsules: A Randomized, Single Dose, 4-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
Wu Q; Wang X; Chen Q; Zou Y; Xu X; Li T; Yu C; Zhu F; Zhang KE; Jia J; Liu Y
Drug Des Devel Ther; 2020; 14():4221-4230. PubMed ID: 33116410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
